Chuck Grassley actually said...

The reality is that these deals between brand-name and generic pharmaceutical companies delay the entry of generic medicines into the market...

This is a very important hearing that we're having to learn more about pay-for-delay agreements.

We should be doing all we can to see that the American consumer has access to lower-priced drugs.

I think they harm drug competition.